Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bacthera Joins Microbiome Therapeutics Innovation Group | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Bacthera Joins Microbiome Therapeutics Innovation Group

Alliance expected to accelerate microbiome therapeutic product development and manufacturing.

By: Anthony Vecchione

The Microbiome Therapeutics Innovation Group (MTIG) announced the addition of Bacthera to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.

Bacthera is a specialized contract development and manufacturing organization (CDMO) that offers services across the Live Biotherapeutics Products (LBP) life cycle and process chain, from technical R&D development to GMP manufacture and QC testing of drug substance and drug product.

Chairman of MTIG & CEO of Siolta Therapeutics, Nikole Kimes, Ph.D., said: “We are excited to welcome Bacthera as the newest MTIG member and the first CDMO to join our coalition. We believe the manufacturing of LBPs is a key component to the growth of the microbiome therapeutics industry as a whole and look forward to working alongside Bacthera and utilizing its world-class industry expertise to help pursue our goal of building tangible policy and regulatory solutions that support the emerging microbiome arena.”

Bacthera CEO, Lukas Schüpbach said: “Bacthera is honored to join the Microbiome Therapeutics Innovation Group. We look forward to working with Nikole and the entire coalition in advancing MTIG’s mission to accelerate microbiome therapeutic product development & manufacturing and expanding the availability of life-changing and life-saving FDA approved microbiome therapies to doctors and patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics